Blake Alkire, MD | |
800 Huntington Ave, Boston, MA 02115-6303 | |
(617) 936-6160 | |
Not Available |
Full Name | Blake Alkire |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 13 Years |
Location | 800 Huntington Ave, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649560707 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 267176 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Massachusetts Eye And Ear Infirmary - | Boston, MA | Hospital |
Massachusetts General Hospital | Boston, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Massachusetts Eye And Ear Associates, Inc | 4486540275 | 337 |
News Archive
The same PinnacleHealth team that participated in a three-year clinical trial designed to evaluate potential benefits of a first-of-its-kind drug eluting ABSORB Bioresorbable Vascular Scaffold (BVS), today announced it deployed the device for the first time after FDA approval for commercial use.
GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).
A new study published in the Canadian Medical Association Journal sheds light on the impact of COVID-19 on ethnocultural community members living in vulnerable circumstances.
Efforts to save the reform effort were teetering "on the brink of collapse Thursday as House and Senate leaders struggled to coalesce around a strategy to rescue the plan," Politico reports.
Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.
› Verified 2 days ago
Entity Name | Massachusetts Eye And Ear Associates, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1932574332 PECOS PAC ID: 4486540275 Enrollment ID: O20040227000123 |
News Archive
The same PinnacleHealth team that participated in a three-year clinical trial designed to evaluate potential benefits of a first-of-its-kind drug eluting ABSORB Bioresorbable Vascular Scaffold (BVS), today announced it deployed the device for the first time after FDA approval for commercial use.
GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).
A new study published in the Canadian Medical Association Journal sheds light on the impact of COVID-19 on ethnocultural community members living in vulnerable circumstances.
Efforts to save the reform effort were teetering "on the brink of collapse Thursday as House and Senate leaders struggled to coalesce around a strategy to rescue the plan," Politico reports.
Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Blake Alkire, MD 800 Huntington Ave, Boston, MA 02115-6303 Ph: (617) 936-6160 | Blake Alkire, MD 800 Huntington Ave, Boston, MA 02115-6303 Ph: (617) 936-6160 |
News Archive
The same PinnacleHealth team that participated in a three-year clinical trial designed to evaluate potential benefits of a first-of-its-kind drug eluting ABSORB Bioresorbable Vascular Scaffold (BVS), today announced it deployed the device for the first time after FDA approval for commercial use.
GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).
A new study published in the Canadian Medical Association Journal sheds light on the impact of COVID-19 on ethnocultural community members living in vulnerable circumstances.
Efforts to save the reform effort were teetering "on the brink of collapse Thursday as House and Senate leaders struggled to coalesce around a strategy to rescue the plan," Politico reports.
Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.
› Verified 2 days ago
Dr. Steven D. Rauch, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Elliott D. Kozin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-6545 | |
Katherine Nicole Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 830 Harrison Ave Ste 1400, Boston, MA 02118 Phone: 617-638-8124 | |
Yoon Sun Chun, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Brigham And Women's Hospital Dept Of Plastic Surgery, Boston, MA 02115 Phone: 617-732-8181 Fax: 617-983-4534 | |
Jaimie Derosa, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 91 Newbury St, Suite 300, Boston, MA 02116 Phone: 617-262-8000 Fax: 617-262-8002 | |
Dr. Usama M Aboelkheir, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Smc8, Boston, MA 02135 Phone: 617-789-5004 Fax: 617-779-6481 | |
Phillip C Song, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3557 |